After the Drug Enforcement Administration (DEA) announced an “emergency” ban on buying kratom at the end of August, a spokesman for the agency said “our goal is to make sure this is available.”
In case that was not confusing enough, the spokesman, Melvin Patterson, also told The Washington Post that kratom, a pain-relieving leaf from Southeast Asia, does not belong in Schedule I, the most restrictive category under the Controlled Substances Act, even though that is where the DEA had just put it. He added that kratom, which the DEA says has “no currently accepted medical use,” is “at a point where it needs to be recognized as medicine.”
The DEA apparently was surprised by the backlash against its ban notice, which included angry calls to Capitol Hill, a demonstration near the White House, and letters from members of Congress. In October the agency withdrew the notice, saying it would delay a decision on kratom to allow time for public comments and input from the Food and Drug Administration. Patterson said criticism of the ban “was eye-opening for me personally,” adding that “I want the kratom community to know that the DEA does hear them.”